Sinopharm Group Co. Ltd.
SHTDY
Other OTC10.81
USD
+0.01
- -
ISIN
US82937K1016
CUSIP
82937K101
Return %
Stock
S&P500
1Y
-10.88
26.53
3Y
-35.46
76.60
5Y
-37.08
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Wanyong Lian
- Full Time Employees
- 108,217
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Address
- Sinopharm Group Building Shanghai People's Republic of China 200023
- IPO Date
- Aug 25, 2016
- Website
- sinopharmgroup.com.cn
- Similar Companies
- Business
- Sinopharm Group Co. Ltd. (SHTDY) operates as China's largest distributor of pharmaceutical and healthcare products and a leading supply chain services provider, with integrated operations across pharmaceutical distribution, medical devices distribution, retail pharmacy, and other businesses including pharmaceutical manufacturing, chemical reagents, and laboratory supplies. The company distributes pharmaceuticals, antibiotics, biological products, Chinese herbal medicines, and medical devices such as diagnostic equipment, surgical instruments, and patient monitoring systems; it provides logistics, value-added services, installation, maintenance, retail chain operations, and franchising for over 10,000 pharmacies including community, direct-to-patient, and dual-channel outlets serving therapeutic areas like oncology, cardiology, infectious diseases, chronic disease management, and wellness products; additionally, it manufactures and sells pharmaceutical products while offering information technology, investment, import-export, consulting, health, and exhibition services. Founded in 2003 and headquartered in Shanghai, China, Sinopharm Group primarily serves the domestic market through a network of approximately 600,000 outlets nationwide and maintains over 1,100 subsidiaries including listed entities China National Medicines Co. Ltd. (600511.SH) and China National Accord Medicines Co. Ltd. (000028.SZ), operating as a subsidiary of China National Pharmaceutical Group Co. Ltd. with around 120,000 employees. Recent developments include the extension of its Suzhou Capsugel joint venture with Lonza for 20 years in May 2025 to bolster capsule manufacturing capabilities; expansion of business collaborations and attendance at the seventh China International Import Expo in November 2024; renewal of distribution agreements such as with Shanghai Henlius Biotech; strategic meetings with global executives from Fresenius Kabi and RX in April 2025 to enhance partnerships; and the appointment of a new president, Mr. Wanyong Lian, in August 2024 alongside institutional investor stake increases by JPMorgan Chase and BlackRock in late 2025.
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary
Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts
Pandemic Accelerates China's Drive Into mRNA Treatments
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
Diversifying Into Top-Ranked Sinopharm
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs